PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
HR+/ HER2- Advanced/ Metastatic Breast Cancer Real World Treatment Patterns and Outcomes
- Conditions
- Breast Cancer
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 975
- Registration Number
- NCT04396626
- Locations
- 🇺🇸
Pfizer United States, New York, New York, United States
Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2 Advanced/Metastatic Breast Cancer on Palbociclib + Aromatase Inhibitor (AI) Combination Therapy
- Conditions
- Breast Cancer
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 242
- Registration Number
- NCT04394247
- Locations
- 🇺🇸
Syapse, San Francisco, California, United States
Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 164
- Registration Number
- NCT04390776
- Locations
- 🇺🇸
Research Centers of America ( Hollywood ), Hollywood, Florida, United States
🇺🇸Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
Study Of Single And Multiple Ascending Doses Of PF-07054894 In Healthy Adult Participants
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT04388878
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: 20-valent pneumococcal conjugate vaccineBiological: 13-valent pneumococcal conjugate vaccine
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1997
- Registration Number
- NCT04382326
- Locations
- 🇺🇸
Children's of Alabama, Birmingham, Alabama, United States
🇺🇸UAB Pediatric Primary Care Clinic at Children's of Alabama, Birmingham, Alabama, United States
🇺🇸Southeastern Pediatric Associates, Dothan, Alabama, United States
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: 13-valent pneumococcal conjugate vaccineBiological: 20-valent pneumococcal conjugate vaccine
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1511
- Registration Number
- NCT04379713
- Locations
- 🇺🇸
Eclipse Clinical Research, Tucson, Arizona, United States
🇺🇸Good Samaritan Family Health Team, Fullerton, California, United States
🇺🇸FocilMed, Oxnard, California, United States
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
- Conditions
- Renal Cell Carcinoma (RCC)
- Interventions
- Drug: Immuno-oncology (IO)
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT04375150
- Locations
- 🇺🇸
Pfizer INC, New York, New York, United States
Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults
- Conditions
- Hemophilia A
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 76
- Registration Number
- NCT04370054
- Locations
- 🇺🇸
NOW Physical Therapy, Mountain View, California, United States
🇺🇸Clinical and Translational Research Unit (CTRU), Palo Alto, California, United States
🇺🇸Lucile Packard Childrens Hospital, Palo Alto, California, United States
Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 391
- Registration Number
- NCT04360187
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Guangzhou First People's Hospital, Guangzhou, Guangdong, China
Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 71
- Registration Number
- NCT04362072
- Locations
- 🇺🇸
UCI Medical Center/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇮🇳Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, DEL, India
🇮🇳Healthcare Global Enterprises, Bengaluru, Karnataka, India